Issue |
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
|
|
---|---|---|
Article Number | 03080 | |
Number of page(s) | 7 | |
Section | Environmental Sustainable Development and Industrial Transformation | |
DOI | https://doi.org/10.1051/e3sconf/202129203080 | |
Published online | 09 September 2021 |
COVID-19 Vaccine Comparison: How to Choose the Best Suiting Vaccine for Different Needs
1 School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore
2 Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, CA
3 Department of Biology, Macalester College, Saint Paul, Minnesota, USA
† These authors contributed equally.
* Corresponding author:
a B180075@e.ntu.edu.sg
b aiyun.lu@mail.utoronto.ca
c xwu@macalester.edu.
Varied measurements have been developed to solve the COVID-19 pandemic, and one of the best ways is vaccines. This paper aims to compare different kinds of vaccines and help people or countries to choose the best suitable vaccine needs based on their different needs. It provides a broader and more detailed analysis of variant vaccines on different levels. In the sequence of technology maturity, inactivated vaccines including CoronaVac, BBIBP-CorV vaccine, and WIBP-CorV vaccine, viral-based vector vaccines including AstraZeneca COVID-19 vaccine and Johnson & Johnson’s COVID-19 vaccine, and mRNA vaccines including Moderna vaccine and Pfizer/BioNTech vaccine have been discussed. There are several important elements of these vaccines, for example, mechanism, effectiveness, and side effects. Different criteria make comparison. For effectiveness, in general, Moderna and Pfizer/BioNTech vaccines could be a better choice. For cost-performance ratio, the AstraZeneca COVID-19 vaccine is the best. As for inoculators’ age and race, old people are suggested to take CoronaVac, and Pfizer/BioNTech vaccine and CoronaVac are suitable for all races. In terms of mutant variant distribution, CoronaVac could be the best choice. Based on safety concerns, inactivated vaccines are better choices. For the developing period, mRNA vaccines win the game. In conclusion, this paper provides further directions for countries seeking the best suitable vaccine for their citizens. After comparing the main vaccines available, we provide a clear view of when countries decide. There would be specific vaccines best suiting specific needs of inoculators and countries.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.